| Ken Haberman, MD | |
|
34612 6th Ave S, Suite 210, Federal Way, WA 98003-8723 | |
| (253) 927-1882 | |
| (253) 927-1439 |
| Full Name | Ken Haberman |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 17 Years |
| Location | 34612 6th Ave S, Federal Way, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225290489 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | A119113 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Community Hospital | Federal way, WA | Hospital |
| Multicare Auburn Medical Center | Auburn, WA | Hospital |
| Tacoma General Allenmore Hospital | Tacoma, WA | Hospital |
| Highline Medical Center | Burien, WA | Hospital |
| St Joseph Medical Center | Tacoma, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Surgical Associates Northwest Pc | 3971596024 | 12 |
News Archive
Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.
A growing body of empirical evidence points to increasing dependency on state largess. The evidence documents as well a number of perverse and disturbing changes that this entitlement state is imposing on society. ... Social Security and Medicare have already made tens of trillions of dollars in future promises that are not covered by their expected funding streams. If and when outside resources are required to honor their promises, these entitlements become transfer programs, not insurance programs.
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School recently identified a new method for safe and effective delivery of medicines to the lungs that can be used for multiple clinical applications, potentially including aerosol vaccination.
› Verified 7 days ago
| Entity Name | Surgical Associates Northwest Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427128198 PECOS PAC ID: 3971596024 Enrollment ID: O20040406000126 |
News Archive
Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.
A growing body of empirical evidence points to increasing dependency on state largess. The evidence documents as well a number of perverse and disturbing changes that this entitlement state is imposing on society. ... Social Security and Medicare have already made tens of trillions of dollars in future promises that are not covered by their expected funding streams. If and when outside resources are required to honor their promises, these entitlements become transfer programs, not insurance programs.
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School recently identified a new method for safe and effective delivery of medicines to the lungs that can be used for multiple clinical applications, potentially including aerosol vaccination.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ken Haberman, MD 34612 6th Ave S, Suite 110, Federal Way, WA 98003-8723 Ph: (253) 927-1882 | Ken Haberman, MD 34612 6th Ave S, Suite 210, Federal Way, WA 98003-8723 Ph: (253) 927-1882 |
News Archive
Image-guided interventions are revolutionizing cancer diagnosis and treatment. MSKCC's new Center for Image-Guided Intervention (CIGI), which opened in June, offers cancer patients the most advanced, minimally invasive diagnostic and treatment options in a unique multidisciplinary setting designed to foster rapid innovations in cancer care.
A growing body of empirical evidence points to increasing dependency on state largess. The evidence documents as well a number of perverse and disturbing changes that this entitlement state is imposing on society. ... Social Security and Medicare have already made tens of trillions of dollars in future promises that are not covered by their expected funding streams. If and when outside resources are required to honor their promises, these entitlements become transfer programs, not insurance programs.
Nuline Pharmaceuticals, LLC announces the introduction of REMESENSE (dipotassium oxalate 3%) TOOTH DESENSITIZER, an Rx Class II medical device now available in the U.S. REMESENSE was introduced globally in 2008. It is presently sold in 16 countries, ranging from England and the European Union to Asia and Africa. Nuline expects to launch REMESENSE in Canada and other countries later this year or by early 2011.
CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).
Investigators at Rutgers Cancer Institute of New Jersey and Rutgers New Jersey Medical School recently identified a new method for safe and effective delivery of medicines to the lungs that can be used for multiple clinical applications, potentially including aerosol vaccination.
› Verified 7 days ago
Anthony Paul Caruso, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S, Suite 210, Federal Way, WA 98003 Phone: 253-927-1882 Fax: 253-927-1439 | |
Yi Chang Hsieh, Urology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S, Suite210, Federal Way, WA 98003 Phone: 253-927-1882 Fax: 253-927-1439 | |
Kevin Joseph Ward, MD Urology Medicare: Medicare Enrolled Practice Location: 34612 6th Ave S, Suite 210, Federal Way, WA 98003 Phone: 253-927-1882 Fax: 253-927-1439 | |
Stephen Haim King, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 34612 6th Ave S Ste 110, Federal Way, WA 98003 Phone: 253-927-1882 |